{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T16:32:26Z","timestamp":1777480346733,"version":"3.51.4"},"reference-count":30,"publisher":"SAGE Publications","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CBM"],"published-print":{"date-parts":[[2021,9,24]]},"abstract":"<jats:p>BACKGROUND: FAS can serve as both an oncogene and a suppresser in different malignancies, and the prognostic value of FAS remains controversial. METHODS: The Oncomine database, KM-Plotter and bc-GenExMiner platform were adopted to analyze the prognostic value of FAS in breast cancer. Breast cancer tissue microarrays were further used to verify these data. The Cell Miner Tool was used to predict the value of FAS mRNA expression in predicting the efficacies of clinical drugs. RESULTS: We found that both FAS mRNA and protein expression level significantly reduced in breast carcinoma. In addition, high FAS expression indicates a better metastatic relapse-free survival. Interestingly, FAS was associated with a better prognosis in different subtypes of breast cancer patients, namely, only in grade II and III, lymph nodal positive or p53 wild-type patients. The data from the Cell Miner Tool revealed that FAS mRNA expression was correlated with the efficacy of the first-line chemotherapeutic taxane agents and target drugs including olaparib and everolimus. CONCLUSIONS: FAS expression correlates with a better prognosis in breast cancer and may provide an effective clinical strategy to predict the sensitivity of taxanes and targeted drugs.<\/jats:p>","DOI":"10.3233\/cbm-203125","type":"journal-article","created":{"date-parts":[[2021,6,4]],"date-time":"2021-06-04T12:32:14Z","timestamp":1622809934000},"page":"207-219","source":"Crossref","is-referenced-by-count":4,"title":["High FAS expression correlates with a better prognosis and efficacy of taxanes and target regents in breast cancer"],"prefix":"10.1177","volume":"32","author":[{"given":"Yi","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Breast Surgery and Oncology, Key Laboratory of Cancer Prevention and Intervention, National Ministry of Education, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China"},{"name":"Key Laboratory of Tumor Microenvironment and Immune Therapy of Zhejiang Province, Hangzhou, Zhejiang, China"},{"name":"Department of Breast Surgery and Oncology, Key Laboratory of Cancer Prevention and Intervention, National Ministry of Education, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuan","family":"Shao","sequence":"additional","affiliation":[{"name":"Department of Breast Surgery and Oncology, Key Laboratory of Cancer Prevention and Intervention, National Ministry of Education, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China"},{"name":"Key Laboratory of Tumor Microenvironment and Immune Therapy of Zhejiang Province, Hangzhou, Zhejiang, China"},{"name":"Department of Breast Surgery and Oncology, Key Laboratory of Cancer Prevention and Intervention, National Ministry of Education, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chenyi","family":"Gao","sequence":"additional","affiliation":[{"name":"Department of Breast Surgery and Oncology, Key Laboratory of Cancer Prevention and Intervention, National Ministry of Education, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China"},{"name":"Key Laboratory of Tumor Microenvironment and Immune Therapy of Zhejiang Province, Hangzhou, Zhejiang, China"},{"name":"Department of Breast Surgery and Oncology, Key Laboratory of Cancer Prevention and Intervention, National Ministry of Education, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danying","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Breast Surgery and Oncology, Key Laboratory of Cancer Prevention and Intervention, National Ministry of Education, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Wu","sequence":"additional","affiliation":[{"name":"Key Laboratory of Tumor Microenvironment and Immune Therapy of Zhejiang Province, Hangzhou, Zhejiang, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuan","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhigang","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Breast Surgery and Oncology, Key Laboratory of Cancer Prevention and Intervention, National Ministry of Education, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China"},{"name":"Key Laboratory of Tumor Microenvironment and Immune Therapy of Zhejiang Province, Hangzhou, Zhejiang, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","reference":[{"issue":"1","key":"10.3233\/CBM-203125_ref1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21387","article-title":"Cancer statistics, 2017","volume":"67","author":"Siegel","year":"2017","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"10.3233\/CBM-203125_ref2","doi-asserted-by":"crossref","first-page":"398","DOI":"10.2174\/156800909788166529","article-title":"Breast cancer: Understanding sensitivity and resistance to chemotherapy and targeted therapies to aid in personalised medicine","volume":"9","author":"Germano","year":"2009","journal-title":"Curr Cancer Drug Targets"},{"key":"10.3233\/CBM-203125_ref3","first-page":"137414","article-title":"Drug resistance and the role of combination chemotherapy in improving patient outcomes","author":"Yardley","year":"2013","journal-title":"Int J Breast Cancer"},{"key":"10.3233\/CBM-203125_ref4","doi-asserted-by":"crossref","unstructured":"B. Nami and Z. Wang, HER2 in breast cancer stemness: A negative feedback loop towards trastuzumab resistance, Cancers (Basel) 9(5) (2017).","DOI":"10.3390\/cancers9050040"},{"key":"10.3233\/CBM-203125_ref5","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/1756-9966-29-49","article-title":"Up-regulation of Fas reverses cisplatin resistance of human small cell lung cancer cells","volume":"29","author":"Wu","year":"2010","journal-title":"J Exp Clin Cancer Res"},{"issue":"14","key":"10.3233\/CBM-203125_ref6","first-page":"1343","article-title":"Fas-mediated signaling enhances sensitivity of human soft tissue sarcoma cells to anticancer drugs by activation of p38 kinase","volume":"1","author":"Li","year":"2002","journal-title":"Mol Cancer Ther"},{"issue":"11","key":"10.3233\/CBM-203125_ref7","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1038\/sj.leu.2400827","article-title":"Deficient activation of the CD95 (APO-1\/Fas) system in drug-resistant cells","volume":"11","author":"Friesen","year":"1997","journal-title":"Leukemia"},{"key":"10.3233\/CBM-203125_ref8","doi-asserted-by":"crossref","first-page":"5238","DOI":"10.1038\/ncomms6238","article-title":"CD95 and CD95L promote and protect cancer stem cells","volume":"5","author":"Ceppi","year":"2014","journal-title":"Nat Commun"},{"issue":"11","key":"10.3233\/CBM-203125_ref9","first-page":"CR457","article-title":"Fas and Fas ligand as prognostic factors in human breast carcinoma","volume":"12","author":"Bebenek","year":"2006","journal-title":"Med Sci Monit"},{"issue":"1A","key":"10.3233\/CBM-203125_ref10","first-page":"215","article-title":"Fas\/Fas-ligand expressions in primary breast cancer are significant predictors of its skeletal spread","author":"Bebenek","year":"2007","journal-title":"Anticancer Res"},{"key":"10.3233\/CBM-203125_ref11","doi-asserted-by":"crossref","first-page":"e2209","DOI":"10.1038\/cddis.2016.102","article-title":"CD95 maintains stem cell-like and non-classical EMT programs in primary human glioblastoma cells","volume":"7","author":"Drachsler","year":"2016","journal-title":"Cell Death Dis"},{"issue":"11","key":"10.3233\/CBM-203125_ref12","doi-asserted-by":"crossref","first-page":"399","DOI":"10.4251\/wjgo.v2.i11.399","article-title":"Role of apoptosis resistance in immune evasion and metastasis of colorectal cancer","volume":"2","author":"Liu","year":"2010","journal-title":"World J Gastrointest Oncol"},{"issue":"30","key":"10.3233\/CBM-203125_ref13","doi-asserted-by":"crossref","first-page":"25530","DOI":"10.1074\/jbc.M112.356279","article-title":"NF-kappaB directly regulates Fas transcription to modulate Fas-mediated apoptosis and tumor suppression","volume":"287","author":"Liu","year":"2012","journal-title":"J Biol Chem"},{"issue":"6","key":"10.3233\/CBM-203125_ref14","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.molmed.2013.03.002","article-title":"CD95 in cancer: Tool or target","volume":"19","author":"Martin-Villalba","year":"2013","journal-title":"Trends Mol Med"},{"issue":"6","key":"10.3233\/CBM-203125_ref15","doi-asserted-by":"crossref","first-page":"3801","DOI":"10.4049\/jimmunol.0801548","article-title":"Fas signal promotes lung cancer growth by recruiting myeloid-derived suppressor cells via cancer cell-derived PGE2","volume":"182","author":"Zhang","year":"2009","journal-title":"J Immunol"},{"issue":"1","key":"10.3233\/CBM-203125_ref16","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.celrep.2014.02.035","article-title":"Death induced by CD95 or CD95 ligand elimination","volume":"7","author":"Hadji","year":"2014","journal-title":"Cell Rep"},{"issue":"5","key":"10.3233\/CBM-203125_ref17","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1038\/sj.bjc.6602732","article-title":"Prognostic impact of FAS\/CD95\/APO-1 in urothelial cancers: Decreased expression of Fas is associated with disease progression","volume":"93","author":"Yamana","year":"2005","journal-title":"Br J Cancer"},{"issue":"9","key":"10.3233\/CBM-203125_ref18","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1038\/onc.2012.126","article-title":"Fas signaling promotes motility and metastasis through epithelial-mesenchymal transition in gastrointestinal cancer","volume":"32","author":"Zheng","year":"2013","journal-title":"Oncogene"},{"issue":"2","key":"10.3233\/CBM-203125_ref19","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.bbrc.2009.07.063","article-title":"Active transcription of the human FAS\/CD95\/TNFRSF6 gene involves the p53 family","volume":"387","author":"Schilling","year":"2009","journal-title":"Biochem Biophys Res Commun"},{"issue":"11","key":"10.3233\/CBM-203125_ref20","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1084\/jem.188.11.2033","article-title":"p53 activates the CD95 (APO-1\/Fas) gene in response to DNA damage by anticancer drugs","volume":"188","author":"Muller","year":"1998","journal-title":"J Exp Med"},{"issue":"2","key":"10.3233\/CBM-203125_ref21","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1002\/(SICI)1097-0215(20000320)89:2<127::AID-IJC5>3.0.CO;2-4","article-title":"Prognostic relevance of altered Fas (CD95)-system in human breast cancer","volume":"89","author":"Mottolese","year":"2000","journal-title":"Int J Cancer"},{"key":"10.3233\/CBM-203125_ref22","doi-asserted-by":"crossref","unstructured":"D. Ghersi, M.L. Willson, M.M. Chan, J. Simes, E. Donoghue and N. Wilcken, Taxane-containing regimens for metastatic breast cancer, Cochrane Database Syst Rev (6) (2015), CD003366.","DOI":"10.1002\/14651858.CD003366.pub3"},{"issue":"6","key":"10.3233\/CBM-203125_ref23","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1007\/s11864-018-0547-8","article-title":"Anthracycline use for early stage breast cancer in the modern era: A review","volume":"19","author":"Jasra","year":"2018","journal-title":"Curr Treat Options Oncol"},{"issue":"3","key":"10.3233\/CBM-203125_ref24","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1111\/cbdd.12893","article-title":"Breast tumor stroma: A driving force in the development of resistance to therapies","volume":"89","author":"Majidinia","year":"2017","journal-title":"Chem Biol Drug Des"},{"key":"10.3233\/CBM-203125_ref25","doi-asserted-by":"crossref","unstructured":"R. Cornelison, D.C. Llaneza and C.N. Landen, Emerging therapeutics to overcome chemoresistance in epithelial ovarian cancer: A mini-review, Int J Mol Sci 18(10) (2017).","DOI":"10.3390\/ijms18102171"},{"issue":"1","key":"10.3233\/CBM-203125_ref26","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/jcb.240560108","article-title":"Intrinsic or acquired drug resistance and metastasis: Are they linked phenotypes","volume":"56","author":"Kerbel","year":"1994","journal-title":"J Cell Biochem"},{"issue":"12","key":"10.3233\/CBM-203125_ref27","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.2217\/fon-2016-0059","article-title":"Creating chemotherapeutic-resistant breast cancer cell lines: Advances and future perspectives","volume":"12","author":"Steding","year":"2016","journal-title":"Future Oncol"},{"issue":"1","key":"10.3233\/CBM-203125_ref28","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1056\/NEJMra043186","article-title":"Trastuzumab\u2013mechanism of action and use in clinical practice","volume":"357","author":"Hudis","year":"2007","journal-title":"N Engl J Med"},{"issue":"1","key":"10.3233\/CBM-203125_ref29","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1158\/0008-5472.CAN-05-2506","article-title":"Blockade of EGFR and ErbB2 by the novel dual EGFR and ErbB2 tyrosine kinase inhibitor GW572016 sensitizes human colon carcinoma GEO cells to apoptosis","volume":"66","author":"Zhou","year":"2006","journal-title":"Cancer Res"},{"issue":"14","key":"10.3233\/CBM-203125_ref30","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1200\/JCO.2014.57.1794","article-title":"CEREBEL (EGF111438): A Phase III, randomized, open-label study of lapatinib plus capecitabine versus trastuzumab plus capecitabine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer","volume":"33","author":"Pivot","year":"2015","journal-title":"J Clin Oncol"}],"container-title":["Cancer Biomarkers"],"original-title":[],"link":[{"URL":"https:\/\/content.iospress.com\/download?id=10.3233\/CBM-203125","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T14:08:16Z","timestamp":1777385296000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.3233\/CBM-203125"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,24]]},"references-count":30,"journal-issue":{"issue":"2"},"URL":"https:\/\/doi.org\/10.3233\/cbm-203125","relation":{},"ISSN":["1875-8592","1574-0153"],"issn-type":[{"value":"1875-8592","type":"electronic"},{"value":"1574-0153","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9,24]]}}}